循环亚酸细胞毒性的综合方法使用In Vitro (2D和3D模型) 和In Silico方法
Carmen Martínez-Alonso1, Luana Izzo2, Yelko Rodríguez-Carrasco1
1Department of Preventive Medicine and Public Health, Food Science, Toxicology and Forensic Medicine, Faculty of Pharmacy and Food Science, University of Valencia, Av. Vicent A Estelles s/n, Burjassot, 46100 Valencia, Spain.
Toxins
|November 26, 2024
概括
环酸 (CPA) 是一种在食物中发现的强有力的神经毒素. 这项研究揭示了CPA随时间和剂量增加细胞毒性,影响人类神经母细胞瘤细胞并预测血脑屏障的透.
科学领域:
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
- 菌类毒理学 菌类毒理学
背景情况:
- 环酸 (CPA) 是一种神经毒性菌毒素,由Aspergillus和Penicillium物种产生的.
- 在受污染的水果,谷物和坚果中通常会发现CPA,这可能会给健康带来潜在的风险.
研究的目的:
- 用2D单层和3D球形来比较CPA在人类神经母细胞瘤SH-SY5Y细胞中的细胞毒性.
- 使用in silico模型评估CPA的毒动力学.
- 评估CPA对球体形态和组织的影响.
主要方法:
- 细胞毒性通过使用MTT测定在不同的CPA暴露时间 (24,48,72小时) 中进行评估.
- 在模型 (SwissADME,admetSAR) 用于ADMEt的配置文件.
- 在CPA暴露后观察到SH-SY5Y球体的形态变化.
主要成果:
- 与3D球形相比,CPA表现出剂量和时间依赖的细胞毒性,在2D单层中IC50值较低.
- 暴露于CPA诱导了SH-SY5Y球体中的形态变化和分离.
- 在分析预测CPA的高胃肠道吸收和血脑屏障透率.
结论:
- 3D球形模型提供了比传统的2D单层更强大的CPA细胞毒性评估.
- 在体中,有毒动力学分析提升了对CPA潜在的系统性影响的理解.
- 这种综合方法为真菌毒素风险评估提供了一个全面的策略.
相关概念视频
In Vitro Drug Dissolution: Compendial Testing Models I
560
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
560
In Vitro Drug Dissolution: Compendial Testing Models II
686
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
686


